More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

Reports Q4 revenue $56.2M, consensus $52.25M. “Strong revenue growth for Fanapt is putting us on a significant growth trajectory for 2025 and ...

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report issued on Wednesday,RTT News reports. They presently have a ...

This article provides an overview of generalized pustular psoriasis (GPP) and its clinical and economic impact, and reviews findings of Effisayil® 2, the first trial to study subcutaneous Spevigo ...

The following is a summary of “Real-World Clinical Characteristics and Treatment Patterns of Generalized Pustular Psoriasis Flares,” published in the February 2025 issue of Dermatology by Rhoads et al ...

Q4 2024 Management View CEO Mihael Polymeropoulos highlighted strong revenue growth for Fanapt, driven by its launch for bipolar I disorder and increased new-to-brand prescriptions by over 160% ...

BI 655130, a new biological entity, has already shown “remarkable efficacy” in early clinical testing with a single dose in patients affected by generalised pustular psoriasis. Results support ...

H.C. Wainwright analyst Emily Bodnar increased the price target on AnaptysBio (NASDAQ:ANAB) shares to $22.00, up from the previous $19.00, while maintaining a Neutral rating on the stock. According to ...

Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725] Draft guidance Technology appraisal guidance 25 February 2025 Tarlatamab for previously treated ...

Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.